Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
General Infectious Disease
How long would you wait to place a new bone flap for a patient with C. auris skull osteomyelitis associated with cranioplasty s/p bone flap removal, who is currently on anti-fungal therapy?
Related Questions
How would you approach treatment duration for patients with persistent candida species fungemia with a history of a prosthetic heart valve but negative TEE/CT PET and no other identifiable source of infection?
Do you ever favor cefazolin over ceftriaxone for bacteremia with susceptible E. coli?
What is your approach to use of D-mannose for prevention of recurrent uncomplicated cystitis?
How long do you continue antibiotics after cholecystostomy tube placement for acute cholecystitis?
For which patients could you consider direct oral amoxicillin challenge as opposed to skin testing for penicillin allergy de-labeling?
When should antibiotics be discontinued for an immunocompetent patient with signs of meningoencephalitis who undergoes an LP without prior administration of antibiotics and the CSF shows a neutrophilic pleocytosis, negative Gram stain, negative PCR Panel, and negative CSF culture at day 3-5?
What is your approach to a patient with undetectable MMR titers checked prior to or during immunosuppression and a history of MMR vaccination in childhood?
Would you consider antifungal prophylaxis for immunocompromised patients with COVID-19 requiring mechanical ventilation, considering the high risk of invasive pulmonary aspergillosis in patients with severe COVID-19?
What is your approach to duration of fidaxomicin in a patient receiving treatment for first C difficile infection while also receiving concurrent antibiotics for an infection?
Do you adhere to the standard 5-day minimum treatment duration for community-acquired pneumonia, or have you used shorter courses for certain low-risk patients?
